Tuesday, December 7, 2021
Dr. Kapil Bahl, Associate Director, T Cell Immunology Infection Disease Research, Moderna Inc.
Host: Ken Campellone
"Impact of mRNA vaccine dosing interval on immunogenicity and durability in mice"
Summary of talk: Background info on Moderna’s platform technology and the impact of prime/boost on vaccine immunogenicity/durability in mice
About Dr. Bahl: Grad student at UMASS Medical investigating factors impacting T cell memory following virus infection. Post-doc at Yale School of Medicine exploring vesicular stomatitis virus vaccine platform for enhancing T cell responses. 7 years at Moderna initially leading flavivirus programs (dengue, zika, and yellow fever) before creating a team focused on evaluating and enhancing T cell responses across pre-clinical/clinical programs.
Seminar Link
For more information, contact: Ciara Hanlon at ciara.hanlon@uconn.edu